Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03671525 · ClinicalTrials.gov registry record · Early Phase 1
Cognitive Effects of Nimodipine in Patients With Schizophrenia
A Early Phase 1 study, sponsored by Johns Hopkins University.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 18
- Enrollment target
NCT03671525: Completed Early Phase 1 study, sponsored by Johns Hopkins University.
NCT03671525 is a Early Phase 1 study that has completed, run by Johns Hopkins University. The registered enrollment target is 18 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03671525, a Early Phase 1 study, has completed, sponsored by Johns Hopkins University.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
This study aims to evaluate the acute effects of nimodipine on cognitive performance in patients with schizophrenia using a battery of cognitive assessments.The subjects will also complete a 30-minute structural and functional MRI scan, with the goal of linking brain activity with working memory performance. Investigators predict that the performance increase induced by nimodipine will be greater in subjects who carry the A allele for the Calcium Voltage-Gated Channel Subunit Alpha1 C (CACNA1C) risk single nucleotide polymorphism (SNP) (rs1006737) in comparison to the response of G carriers.
Interventions
- DRUG Placebo oral capsule
- DRUG Nimodipine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2018-10-05 |
| Est. Completion | 2023-05-12 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03671525
The ClinicalTrials.gov registry entry for NCT03671525 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Johns Hopkins University, which has 1,448 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo oral capsule is the first listed.
NCT03671525 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03671525 about?
NCT03671525 is a clinical study titled "Cognitive Effects of Nimodipine in Patients With Schizophrenia". This study aims to evaluate the acute effects of nimodipine on cognitive performance in patients with schizophrenia using a battery of cognitive assessments.The subjects will also complete a 30-minute structural and functional MRI scan, with the goal of linking brain activity with working memory per...
What is the current status of trial NCT03671525?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 18 participants. The study started on 2018-10-05. Estimated completion is 2023-05-12.
What interventions are being tested in trial NCT03671525?
The interventions under investigation include: Placebo oral capsule (DRUG), Nimodipine (DRUG).
Who is sponsoring clinical trial NCT03671525?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.